Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Leukemia Research|January 1, 2021
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patientsGiovanni Marconi, Stefano De Polo, Giovanni Martinelli, et al.
Frontiers in Immunology|February 17, 2022
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still MattersSarah Parisi, Loredana Ruggeri, Elisa Dan, et al.
Cancer Medicine|March 31, 2023
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical studyGiovanni Marconi, Anna Candoni, Roberta Di Nicola, et al.
European Journal of Haematology|March 8, 2020
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemiaGiovanni Marconi, Annalisa Talami, Maria Chiara Abbenante, et al.
Blood Neoplasia|June 2, 2025
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.
Cancer|March 30, 2025
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life settingJacopo Nanni, Irene Azzali, Cristina Papayannidis, et al.
Leukemia|July 1, 2021
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutationsGiorgia Simonetti, Carlo Mengucci, Antonella Padella, et al.
American Journal of Hematology|January 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating AgentsGiovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
Blood Advances|March 6, 2025
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AMLGiovanni Marconi, Alfonso Piciocchi, Ernesta Audisio, et al.
Cancer|January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaElisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Pageof 3